<DOC>
	<DOC>NCT01269671</DOC>
	<brief_summary>IND application was submitted to FDA on November 17th.</brief_summary>
	<brief_title>Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Peppermint oil</mesh_term>
	<mesh_term>Simethicone</mesh_term>
	<criteria>To participate in this study, the child/teen must be a patient of the FAP Clinic/GI Clinic in the Division of Gastroenterology at the Children's Hospital of Wisconsin, and have a parent or legal guardian who is willing to participate. Children aged 818 years will be eligible for inclusion in the study. Children or parents who are nonEnglish speaking, or parents and/or children with cognitive delay that precludes comprehension and completion of questionnaires will be excluded from participating in this registry.</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Functional Abdominal Pain</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS</keyword>
	<keyword>Functional Dyspepsia</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Simethicone</keyword>
	<keyword>Peppermint Oil</keyword>
	<keyword>mentharil</keyword>
	<keyword>functional bowel disorders</keyword>
	<keyword>quality of life</keyword>
</DOC>